Kessler Topaz Meltzer & Check, LLP is Lead Counsel in a securities fraud class action against pharmaceutical company Endo International, plc (NASDAQ: ENDP) and certain of its senior officers, captioned Bier v. Endo International, PLC, et al., Case No. 2:2017-cv-03711 (E.D. Pa.).
The case arises from Defendants’ representations to investors about the safety and abuse-deterrent properties of one of Endo’s principal and most profitable drugs, Reformulated OPANA ER. Plaintiffs have asserted that in making false claims to investors about the safety and abuse-deterrent qualities of Reformulated OPANA ER, Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Sections 11 and 15 of the Securities Act of 1933 (the “Securities Act”).
The action seeks to recover losses suffered by investors who purchased Endo’s common stock between November 30, 2012 and June 8, 2017, inclusive (the “Class Period”). Additionally, the action seeks to recover losses of investors who purchased Endo common stock in Endo’s June 2, 2015 secondary offering of 24,024,025 shares at $83.25 per share.
On December 10, 2018, the Court denied the Defendants’ motion to dismiss and has allowed the case to proceed to trial.
If you purchased shares of Endo (NASDAQ: ENDP) during the Class Period and would like to learn more about this litigation, please contact us at 888-299-7706 or email@example.com, or fill out our online form.